6 completed, 1 enrolling by invitation, 1 withdrawn. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Enrolling by invitation 1, Withdrawn 1 |
Follow Graft Rejection: new trials by email Literature Review of Graft Rejection trials Research Report on Graft Rejection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Fingolimod, Placebo - Interstitial Fibrosis, Kidney Transplant; Complications | Phase 2 | Enrolling by invitation | The Methodist Hospital Research Institute | 20 | 2022-07-28 | 2025-03-14 |
| Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation [18F]FSPG - Graft Rejection, Heart Transplantation | Phase 2 | Completed | Asan Medical Center | 7 | 2020-11-18 | 2023-07-20 |
| A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection Placebo, C1 Esterase Inhibitor (Human) - Graft Rejection | Phase 2 | Completed | Shire | 18 | 2011-08-24 | 2021-06-11 |
| Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation plasmapheresis and IVIG, recombinant C1 inhibitor - Graft Rejection, Kidney Transplantation | Phase 2 | Withdrawn | Pharming Technologies B.V. | 2010-12-01 | 2012-02-17 | |
| Randomized Trial for Mixed Acute Rejection Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib - Graft Rejection | Phase 2 | Completed | University of Cincinnati | 30 | 2008-09-01 | 2016-01-27 |
| A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)] - Renal Transplantation, Graft Rejection | Phase 2 | Completed | Genzyme, a Sanofi Company | 150 | 2003-06-01 | 2015-03-18 |
| Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney Belatacept, Cyclosporine, Mycophenolate mofetil (MMF) - Graft Rejection, Kidney Transplantation | Phase 2 | Completed | Bristol-Myers Squibb | 230 | 2001-03-01 | 2014-01-13 |
| Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys Alemtuzumab and DSG - Graft Rejection, Kidney Disease | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 5 | 1999-11-01 | 2016-10-27 |
Rejection, Psychology (2) · Fibrosis (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Pulmonary Fibrosis (1)
Behavior (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Social Behavior (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Chronic Disease (1) · Disease Attributes (1) · Kidney Diseases (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Renal Insufficiency (1)
thymoglobulin (2) · 4-(3-fluoropropyl)glutamic acid (1) · Abatacept (1) · Acetaminophen (1) · Adrenal Cortex Hormones (1) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Bortezomib (1) · Complement C1 Inhibitor Protein (1) · Cyclosporine (1) · Diphenhydramine (1) · Fingolimod Hydrochloride (1) · Histamine Antagonists (1) · Immunoglobulins, Intravenous (1) · Methylcellulose (1)
Asan Medical Center (1) · Bristol-Myers Squibb (1) · Genzyme, a Sanofi Company (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Pharming Technologies B.V. (1) · Shire (1) · The Methodist Hospital Research Institute (1) · University of Cincinnati (1)
United States (7) · Germany (1) · South Korea (1)
Dae Hyuk Moon, MD (1) · E. Steve Woodle, MD (1) · Hans Sollinger, MD, PhD (1)